Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct factor XA inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement - Eriksson,B.I.; Borris,L.C.; Dahl,O.E. (Thromb Res, 2007)